- Home
- ZH vs LRMR Comparison
ZH vs LRMR Comparison
Compare ZH & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZH | LRMR |
|---|---|---|
| Founded | 2011 | N/A |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 307.6M | 332.1M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | ZH | LRMR |
|---|---|---|
| Price | $3.27 | $3.98 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $16.71 |
| AVG Volume (30 Days) | 273.2K | ★ 1.4M |
| Earning Date | 11-25-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.17 | N/A |
| Revenue | ★ $416,437,241.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $20.08 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.19 | $1.61 |
| 52 Week High | $6.32 | $5.37 |
Technical Indicators
Market Signals| Indicator | ZH | LRMR |
|---|---|---|
| Relative Strength Index (RSI) | 35.71 | 54.97 |
| Support Level | $3.29 | $3.34 |
| Resistance Level | $3.48 | $4.04 |
| Average True Range (ATR) | 0.13 | 0.26 |
| MACD | 0.02 | 0.03 |
| Stochastic Oscillator | 11.59 | 75.93 |
Price Performance
Historical ComparisonAbout ZH Zhihu Inc. (every two of each representing one ordinary share)
Zhihu Inc is predominantly engaged in the operation of one online content community and monetizes through paid membership services, advertising services, content-commerce solutions services, and vocational training in China. It generates revenues from Advertising services, Paid membership services, Content-commerce solutions, and Others. It derives all its revenues within China.
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.